<DOC>
	<DOCNO>NCT02391831</DOCNO>
	<brief_summary>NatHis-SMA prospective , longitudinal interventional study natural history patient type 2 3 Spinal Muscular Atrophy ( SMA ) . The purpose study characterize disease course 2 year identify prognostic variable disease biomarkers SMA progression , well determine best outcome measure therapeutic approach .</brief_summary>
	<brief_title>Prospective Study Natural History Patients With Type 2 3 Spinal Muscular Atrophy</brief_title>
	<detailed_description />
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Muscular Atrophy , Spinal</mesh_term>
	<mesh_term>Muscular Atrophy</mesh_term>
	<criteria>INCLUSION CRITERIA Type 2 3 spinal muscular atrophy genetically confirm Age superior equal 2 year old 30 year age include For patient old 6 year old , willing able comply protocol requirement procedure . For nonambulant patient , able sit upright wheelchair least three hour Patients 18 year age parent ( ) /legal guardian ( ) patient &lt; 18 year age must provide write informed consent prior participate study inform assent obtain minor least 7 year age require regulation . In France : Affiliated beneficiary social security category EXCLUSION CRITERIA Previously treat investigational drug within 6 month prior recruitment study . Other condition may significantly interfere assessment SMA clearly related disease Current anticipate participation therapeutic investigational clinical study . Patients specific contraindication MRI ( i.e . metallic foreign body , claustrophobia , others deem prohibitive investigator ) allow participate , MRI perform . For woman : pregnancy current breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>SMA</keyword>
	<keyword>Spinal Muscular Atrophy</keyword>
	<keyword>Neuromuscular disease</keyword>
</DOC>